Recombinant Human C1 Esterase Inhibitor (Ruconest) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial in the US
Latest Information Update: 21 Feb 2024
At a glance
- Drugs Conestat alfa (Primary)
- Indications Acute lung injury; COVID 2019 infections
- Focus Therapeutic Use
- Acronyms PROTECT-COVID-19-US
- Sponsors Pharming Group NV
- 02 Jun 2022 Status changed from recruiting to completed.
- 13 Sep 2021 According to a Pharming Group NV media release, the company will analyze the full results as it will design future clinical trials with RUCONEST for the treatment of COVID-19, as well as other serious conditions.
- 13 Sep 2021 According to a Pharming Group NV media release, study has been concluded and results will be published in peer-review medical journals.